BSE: 512529 | NSE: SEQUENT | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sequent Scientific Ltd is a average quality company.
The key valuation ratios of Sequent Scientific Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Sequent Scientific Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -3.9% | 2.5% | 1.1% | 4.8% | 9.2% | 12.6% | 16.2% | 7% | -9.7% | -0.6% | - |
| Value Creation Index ⓘ | -1.3 | -0.8 | -0.9 | -0.7 | -0.3 | -0.1 | 0.2 | -0.5 | -1.7 | -1.0 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 443 | 606 | 684 | 848 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,370 | 1,449 |
| Sales YoY Gr. | - | 36.8% | 12.8% | 24% | 22.6% | 13.5% | 15.5% | 3.8% | 0.6% | -3.6% | - |
| Adj EPS ⓘ | -3.6 | -0.8 | -0.1 | 0.2 | 2.2 | 3 | 4 | 1.5 | -4.5 | -0.5 | 0.7 |
| YoY Gr. | - | NA | NA | NA | 1042.1% | 36.4% | 35.5% | -63.6% | -408.9% | NA | - |
| BVPS (₹) ⓘ | 3.8 | 38.7 | 39.4 | 25.9 | 27.9 | 27.1 | 29 | 26 | 25.8 | 23.2 | 27.3 |
| Adj Net Profit ⓘ | -54.2 | -19.6 | -1.6 | 4.7 | 53.6 | 73.4 | 99.6 | 36.4 | -112 | -12.1 | 16 |
| Cash Flow from Ops. ⓘ | -23.6 | -0.1 | -7.2 | 45.2 | 116 | 115 | 115 | 30.6 | 16.8 | 30.6 | - |
| Debt/CF from Ops. ⓘ | -20.1 | -5782.5 | -57.8 | 6.7 | 2.8 | 3 | 2 | 10.3 | 23.7 | 14.8 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 13.4% | 5.7% | 0.2% | -3.6% | ||||
| Adj EPS ⓘ | NA | -174.3% | -149.6% | NA | ||||
| BVPSⓘ | 22.4% | -3.6% | -7.1% | -9.9% | ||||
| Share Price | 8.7% | 24% | 2.7% | 77.2% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -73.2 | -3.8 | -0.2 | 0.6 | 7.9 | 10.5 | 14.1 | 5.1 | -16.2 | -1.8 | 2.6 |
| Op. Profit Mgn % ⓘ | 4.4 | 9.6 | 8.5 | 10.3 | 12.8 | 14.9 | 15.7 | 7.8 | 1.7 | 5.6 | 9.4 |
| Net Profit Mgn % ⓘ | -12.5 | -2.9 | -0.6 | 1.7 | 6 | 7.3 | 8 | 2.8 | -8 | -0.4 | 1.1 |
| Debt to Equity ⓘ | 8.3 | 0.3 | 0.4 | 0.5 | 0.5 | 0.5 | 0.3 | 0.5 | 0.6 | 0.8 | 0.4 |
| Working Cap Days ⓘ | 244 | 227 | 275 | 246 | 206 | 190 | 179 | 196 | 199 | 199 | 101 |
| Cash Conv. Cycle ⓘ | 66 | 79 | 93 | 89 | 79 | 73 | 80 | 95 | 102 | 105 | 32 |
Return on Equity has increased versus last 3 years average to 2.60%
Debt to equity has declined versus last 3 years average to 0.78
Sales growth has been subdued in last 3 years 0.20%
Net Profit has been subdued in last 3 years -149.62%
Sales growth is not so good in last 4 quarters at 2.49%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.7 | 0.7 |
| TTM Sales (₹ Cr.) | 179 | 1,449 |
| BVPS (₹.) ⓘ | 44.5 | 27.3 |
| Reserves (₹ Cr.) ⓘ | 1,060 | 631 |
| P/BV ⓘ | 4.39 | 7.16 |
| PE ⓘ | 284.99 | 295.81 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 91.85 / 240.90 |
| All Time Low / High (₹) | 0.40 / 336.40 |
| Market Cap (₹ Cr.) | 4,874 |
| Equity (₹ Cr.) | 50 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 443 | 606 | 684 | 848 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,370 |
| Operating Expenses ⓘ | 425 | 551 | 641 | 765 | 914 | 1,009 | 1,152 | 1,303 | 1,409 | 1,308 |
| Manufacturing Costs | 78 | 99 | 70 | 74 | 101 | 108 | 125 | 128 | 129 | 109 |
| Material Costs | 225 | 299 | 357 | 462 | 543 | 605 | 695 | 793 | 834 | 760 |
| Employee Cost | 61 | 87 | 106 | 114 | 146 | 165 | 187 | 231 | 258 | 251 |
| Other Costs ⓘ | 61 | 67 | 107 | 115 | 125 | 131 | 145 | 152 | 187 | 189 |
| Operating Profit ⓘ | 18 | 55 | 43 | 83 | 125 | 170 | 210 | 109 | 12 | 61 |
| Operating Profit Margin (%) | 4.1% | 9.1% | 6.3% | 9.8% | 12.0% | 14.4% | 15.4% | 7.7% | 0.8% | 4.5% |
| Other Income ⓘ | 10 | 13 | 11 | 17 | 9 | 10 | 10 | 11 | 6 | 11 |
| Interest ⓘ | 43 | 38 | 28 | 33 | 33 | 36 | 24 | 16 | 36 | 48 |
| Depreciation ⓘ | 32 | 46 | 40 | 41 | 42 | 51 | 51 | 52 | 56 | 62 |
| Exceptional Items ⓘ | -17 | 0 | 0 | -2 | 0 | 0 | -9 | 0 | -65 | -17 |
| Profit Before Tax ⓘ | -63 | -15 | -14 | 24 | 59 | 94 | 137 | 53 | -138 | -55 |
| Tax ⓘ | 3 | 3 | -1 | 13 | 2 | 12 | 32 | 8 | -16 | -25 |
| Profit After Tax | -67 | -18 | -14 | 10 | 57 | 82 | 104 | 45 | -122 | -30 |
| PAT Margin (%) | -15.1% | -3.0% | -2.0% | 1.2% | 5.5% | 7.0% | 7.7% | 3.2% | -8.6% | -2.2% |
| Adjusted EPS (₹) | -0.7 | -0.8 | -0.6 | 17.3 | 2.0 | 2.8 | 3.8 | 1.7 | -4.9 | -1.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 1% | 10% | 0% | 13% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 57 | 922 | 961 | 630 | 688 | 673 | 720 | 645 | 642 | 579 |
| Share Capital ⓘ | 30 | 48 | 49 | 49 | 49 | 50 | 50 | 50 | 50 | 50 |
| Reserves ⓘ | 27 | 874 | 912 | 581 | 638 | 623 | 670 | 595 | 593 | 529 |
| Minority Interest | 147 | 2 | 17 | 37 | 40 | 45 | 49 | 48 | 50 | 56 |
| Debt | 455 | 267 | 360 | 256 | 275 | 297 | 197 | 282 | 332 | 389 |
| Long Term Debt | 250 | 211 | 165 | 104 | 148 | 150 | 94 | 122 | 150 | 143 |
| Short Term Debt | 204 | 56 | 195 | 152 | 127 | 147 | 103 | 160 | 182 | 246 |
| Trade Payables | 91 | 144 | 203 | 160 | 209 | 220 | 227 | 258 | 244 | 260 |
| Others Liabilities ⓘ | 172 | 203 | 362 | 259 | 189 | 228 | 251 | 254 | 214 | 178 |
| Total Liabilities ⓘ | 922 | 1,538 | 1,904 | 1,343 | 1,402 | 1,463 | 1,443 | 1,487 | 1,484 | 1,462 |
Fixed Assets | ||||||||||
| Gross Block | 596 | 644 | 790 | 582 | 638 | 762 | 753 | 825 | 940 | 959 |
| Accumulated Depreciation | 122 | 57 | 105 | 106 | 140 | 186 | 218 | 261 | 335 | 367 |
| Net Fixed Assetsⓘ | 474 | 586 | 684 | 476 | 498 | 577 | 536 | 564 | 605 | 592 |
| CWIP ⓘ | 39 | 24 | 33 | 18 | 23 | 13 | 31 | 12 | 55 | 16 |
| Investmentsⓘ | 59 | 428 | 428 | 239 | 180 | 171 | 83 | 38 | 0 | 4 |
| Inventories | 94 | 135 | 161 | 159 | 200 | 219 | 264 | 348 | 346 | 346 |
| Trade Receivables | 115 | 192 | 255 | 258 | 278 | 319 | 346 | 329 | 341 | 336 |
| Cash Equivalents | 38 | 25 | 47 | 42 | 72 | 76 | 56 | 59 | 42 | 70 |
| Others Assetsⓘ | 101 | 148 | 296 | 150 | 151 | 88 | 127 | 136 | 94 | 99 |
| Total Assets ⓘ | 922 | 1,538 | 1,904 | 1,343 | 1,402 | 1,463 | 1,443 | 1,487 | 1,484 | 1,462 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -24 | 0 | -7 | 45 | 116 | 115 | 115 | 31 | 17 | 31 |
| PBT ⓘ | -8 | -14 | -17 | 446 | 59 | 94 | 145 | 53 | -138 | -55 |
| Adjustment ⓘ | 36 | 84 | 123 | -314 | 84 | 91 | 84 | 94 | 221 | 145 |
| Changes in Working Capital ⓘ | -54 | -71 | -104 | -78 | -28 | -58 | -71 | -89 | -52 | -46 |
| Tax Paid ⓘ | 3 | 1 | -9 | -9 | 1 | -12 | -44 | -27 | -15 | -14 |
| Cash Flow From Investing Activity ⓘ | -155 | -316 | -116 | 7 | -68 | -72 | 10 | -96 | -65 | -6 |
| Capex | -113 | -96 | -75 | -45 | -24 | -40 | -45 | -31 | -75 | -12 |
| Net Investments | 51 | -119 | 7 | 48 | 12 | -39 | 53 | -41 | 24 | -8 |
| Others ⓘ | -92 | -101 | -48 | 4 | -56 | 7 | 2 | -23 | -14 | 14 |
| Cash Flow From Financing Activityⓘ | 179 | 309 | 147 | -57 | -20 | -43 | -139 | 67 | 32 | -1 |
| Net Proceeds from Shares ⓘ | 36 | 540 | 41 | 1 | 2 | 2 | 10 | 11 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 78 | -29 | 20 | -51 | 45 | 0 | -74 | 36 | 22 | -4 |
| Interest Paid ⓘ | -49 | -40 | -37 | -33 | -26 | -33 | -23 | -16 | -36 | -45 |
| Dividend Paid ⓘ | 0 | 0 | 0 | -5 | 0 | -5 | 0 | -12 | 0 | 0 |
| Others ⓘ | 114 | -162 | 124 | 31 | -40 | -7 | -53 | 48 | 46 | 48 |
| Net Cash Flow ⓘ | 1 | -7 | 24 | -5 | 28 | 0 | -14 | 2 | -16 | 23 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -159.4 | -3.67 | -1.47 | 1.28 | 8.63 | 12.06 | 15 | 6.56 | -18.95 | -4.85 |
| ROCE (%) | -3.91 | 2.5 | 1.05 | 4.84 | 9.24 | 12.59 | 16.24 | 7.01 | -9.71 | -0.6 |
| Asset Turnover Ratio | 0.6 | 0.51 | 0.4 | 0.52 | 0.77 | 0.84 | 0.96 | 0.98 | 0.98 | 0.96 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | 4.5 | 2.04 | 1.4 | 1.11 | 0.69 | N/A | N/A | Working Capital Days |
| Receivable Days | 78 | 90 | 118 | 110 | 93 | 90 | 87 | 85 | 84 | 88 |
| Inventory Days | 77 | 67 | 78 | 69 | 62 | 64 | 64 | 78 | 87 | 90 |
| Payable Days | 167 | 143 | 178 | 144 | 124 | 130 | 118 | 112 | 110 | 121 |
P I Drugs & Pharmaceuticals Ltd. established in 1991 is a leading manufacturer, exporter of specialized quality formulations having an objective of fulfilling the diverse demands of pharmaceutical industry.
P I Drugs & Pharmaceuticals Ltd. specializes in the manufacturing of the formulation belonging to anthelmintic & anti-parasitic segment.
In September 2007 PI Drugs purchased the pharma division of Transchem Limited.
The company is engaged in the business of human health & animal health and enjoys high Image for distribution in domestic as well as international markets.
They have a specialized and dedicated WHO - GMP accredited manufacturing plant for the manufacture of API's. It exports to all major markets like Europe, South America, Australia, Asia and Africa.
They started with the introduction of Albendazole and has developed core competency in chemistry of Benzimadazole in very short time.
Product range of the company includes:
Human / Veterinary Formulations
Honey Bee Medicine
Human / Veterinary API's
Veterinary API’s
Human API's
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
